BIO89-100
Phase 3Small molecule
89bioBIO89-100 is one of 45 small molecule programs targeting NASH/MASH. It is currently in Phase 3.
2
Indications
2
Total Trials
1
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
252 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1BIO89-100
89bioPhase 3
Proamatine
TakedaPreclinical
Crestor
AstraZenecaPreclinical
Thalomid
Bristol-Myers SquibbPreclinical
Farxiga
AstraZenecaPreclinical
Azulfidine
PfizerPreclinical
Dobutrex
Eli LillyPreclinical
HEPCLUDEX
GileadPreclinical
Cipro
BayerPreclinical
Coreg
Akero TherapeuticsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BIO89-100. EMBL-EBI & Wellcome Sanger Institute.
- [4]